Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings

Core Insights - Ultragenyx reported revenue of $159.93 million for the quarter ended September 2025, reflecting a year-over-year increase of 14.7% [1] - The company's EPS was -$1.81, a decline from -$1.40 in the same quarter last year, and fell short of the consensus estimate of -$1.23 by 47.15% [1][3] - The revenue fell short of the Zacks Consensus Estimate of $167.55 million, resulting in a surprise of -4.55% [1] Revenue Breakdown - Dojolvi generated $24.28 million in product sales, below the average estimate of $25.96 million, marking a year-over-year increase of 13.6% [4] - Evkeeza achieved $16.72 million in product sales, exceeding the estimated $13.24 million, representing a significant year-over-year growth of 56.9% [4] - Mepsevii reported $7 million in product sales, which was below the average estimate of $8.82 million, indicating a year-over-year decline of 27.2% [4] - Total Crysvita revenue was $111.94 million, falling short of the average estimate of $119.46 million [4] - Overall product sales reached $94.99 million, surpassing the average estimate of $89.79 million, with a year-over-year increase of 23% [4] - Royalty revenue was $64.94 million, below the estimated $78.87 million, but showed a year-over-year increase of 4.3% [4] Stock Performance - Ultragenyx shares have returned +10.9% over the past month, outperforming the Zacks S&P 500 composite's +2.1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]